Application of taurolidine in virus resistance

A technology of taurolidine and viruses, which is applied in the direction of antiviral agents, medical preparations containing active ingredients, respiratory diseases, etc., can solve problems such as no research reports on the application of antiviral activity, and achieve significant protective effects, The effect of expanding the scope of efficacy and prolonging the survival time

Active Publication Date: 2021-10-12
ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE +1
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Until July 2020, there were more than 260 foreign literature searches on taurolidine research reports. Most of the studies focused on the exploration of the role of taurolidine in tumor-related signaling pathways, while the application of taurolidine in terms of antiviral activity has not been reported. see research report

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of taurolidine in virus resistance
  • Application of taurolidine in virus resistance
  • Application of taurolidine in virus resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 The effect of taurolidine on cell safety

[0060] MDCK, Vero-E6, and F81 cells were stored in liquid nitrogen, taken out and recovered, and passed on for three consecutive generations. After the cells grew well, they were used for experimental research. MDCK, Vero-E6, and F81 cells were seeded in 96-well plates, and the number of cells in each well was 1 × 10. 5 , at 37°C, 5% CO 2 Incubate overnight in a constant temperature cell incubator. When the cell density is 60-70%, add 2% FBS DMEM containing different concentrations of taurolidine (initial concentration 4mg / ml, with 10-fold gradient to dilute the drug to be tested, a total of 10 concentrations) in 2% FBS DMEM. 100 μL / well of solution, and 4 replicate wells were measured for each concentration. A blank cell control and a PBS control were also set up, and 4 repetitions were performed, and the culture was continued, and the cell status was observed under a microscope every day. On the second day of do...

Embodiment 2

[0062] Embodiment 2 Taurolidine inhibits the detection result of influenza virus infectivity

[0063] The MDCK cells were stored in liquid nitrogen, taken out and recovered, and passed on for three consecutive generations. After the cells grew well, they were used for experimental research. The preserved H3N2 influenza virus strain was slowly thawed on ice, inoculated into a monolayer of MDCK cells (less than 24 hours), and cultured for 72-96 hours, and the virus liquid was harvested according to the cytopathic state. and determine its content, with TCID 50 / 100μl is the calculation unit.

[0064]The drug is mixed with the H3N2 subtype influenza virus liquid obtained above and then inserted into the cells. The well-growing MDCK cells were digested with trypsin to calculate the cell content, and seeded in a 96-well plate, the number of cells per well was 1×10 5 . Drug effect studies were performed within 12 hours of seeding and when the cells were in a monolayer state. Ino...

Embodiment 3

[0067] Embodiment 3 Taurolidine inhibits the propagation of influenza virus in cells

[0068] 1. Experimental materials

[0069] 1.1 Cells: human lung cancer cell A549 and African green monkey kidney cell MDCK, from the Virology Laboratory of the Military Veterinary Research Institute;

[0070] 1.2 Virus strains: H1N1-UI182, H1N1-PR8, H3N2 and H5N1 viruses, from the Virology Laboratory of the Military Veterinary Research Institute;

[0071] 1.3 Reagents: DMEM, 0.25% trypsin, FBS, PBS (pH=7.0);

[0072] 1.4 Instrument consumables: pipette and supporting tips, 1.5mL centrifuge tube, ice box, ice maker, biological safety cabinet, carbon dioxide incubator.

[0073] 2. Experimental method

[0074] 2.1 Cell culture: Resuscitate A549 and MDCK, pass three generations continuously, and use for experimental research after the cells grow well;

[0075] 2.2 Virus culture: Put the preserved virus liquid on ice to slowly melt and inoculate it in a single layer of MDCK (no more than 24 h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides an application of taurolidine in virus resistance. Specifically, the invention provides use of the taurolidine or a derivative thereof, a prodrug, a solvate or a pharmaceutically acceptable salt thereof, or a composition containing the taurolidine or the derivative thereof, the prodrug, the solvate or the pharmaceutically acceptable salt thereof in preparation of antiviral drugs. Research results show that the taurolidine can significantly inhibit influenza virus and coronavirus at a cellular level. In addition, in-vivo experiments prove that taurolidine has a remarkable protection effect on lungs and can prolong the survival time of mice infected with influenza viruses or SARS-CoV-2 viruses. Therefore, the taurolidine can be used for preventing and treating lung diseases caused by the influenza virus or the coronavirus. The research result of the application expands the efficacy range of the taurolidine, and provides a research basis and opens up a new direction for research and development of drugs for preventing or treating pulmonary infection caused by the viruses.

Description

[0001] This application is based on the CN application number of 202010638926.9, the application date of July 6, 2020, the CN application number of 202010639186.0, the application date of July 6, 2020, and the CN application number of 202010994928.1, and the application date of September 2020. On the basis of the application on the 21st, and claiming its priority, the disclosure content of this CN application is hereby incorporated into this application in its entirety. technical field [0002] The invention relates to the field of drug therapy, in particular to the use of taurolidine in the preparation of antiviral drugs, especially in the preparation of drugs for treating and / or preventing novel coronavirus or influenza virus infection. Background technique [0003] Coronaviruses are a large group of viruses that exist widely in nature. In biological classification, coronaviruses belong to the order Nidovirales, the family Coronaviridae, and the genus Coronavirus. The dia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/549A61P31/14A61P11/00A61P31/16
CPCA61K31/549A61P31/14A61P11/00A61P31/16A61P31/12A61P31/18
Inventor 高玉伟苏忠李元果李松吕朝相王铁成钟武向海洋周彤孙伟洋王雪峰周博李恩涛冯娜赵永坤杨松涛夏咸柱
Owner ACAD OF MILITARY SCI PLA CHINA ACAD OF MILITARY MEDICAL SCI INST OF MILITARY VETERINARY MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap